Patent ID: 11963521
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Biotechnology (Chemistry)
Classification: CPC A  C | IPC A  C  G

Claim 1:
2. A targeting vector for humanizing an endogenous IL-4 gene in a rodent, comprising
a nucleic acid sequence of a human IL-4 gene, flanked by nucleic acid sequences that are homologous to nucleic acid sequences at a rodent IL-4 locus and mediate integration of the nucleic acid sequence of the human IL-4 gene into the rodent IL-4 locus,
wherein the nucleic acid sequence of the human IL-4 gene comprises the ATG initiation codon of exon 1 through exon 4 of the human IL-4 gene;
wherein integration of the nucleic acid sequence of the human IL-4 gene into the rodent IL-4 locus results in a replacement of a genomic fragment of the rodent IL-4 gene to form a humanized IL-4 gene,
wherein the genomic fragment of the rodent IL-4 gene being replaced comprises the ATG initiation codon of exon 1 through exon 4 of the rodent IL-4 gene, and
wherein expression of the humanized IL-4 gene is under control of rodent IL-4 regulatory elements at the endogenous rodent IL-4 locus, and
wherein the rodent is a mouse.